Effect of anesthetics on neuropathologic sequelae of status epilepticus in rats.
We compared the efficacy of four different classes of anesthetics to arrest the progression of brain damage after chemoconvulsant-induced seizures in rats. In two series of experiments, ventilated, paralyzed Long-Evans rats were subjected to 30 or 45 min of continuous seizures induced by intravenous (IV) mercaptopropionic acid (MPA) or inhaled flurothyl, respectively. In the first series, seizures produced with MPA were treated with: 1) thiopental, 15 mg/kg IV bolus (controls); 2) thiopental, 27 mg/kg IV followed by 20.9 mg.kg-1.h-1 for 2 h; 3) isoflurane 4% inhaled concentration for 1 min followed by 1%-2% for 2 h; 4) ketamine 30 mg/kg IV followed by 9.12 mg.kg-1.h-1 for 2 h; 5) midazolam 25 mg/kg IV followed by 9.7 mg.kg-1.h-1 for 2 h. In a second series, seizures were produced by flurothyl and, based on suggestive results in the MPA series, control rats were compared with rats receiving midazolam 25 mg/kg IV followed by 9.7 mg.kg-1.h-1. In all instances, seizure activity, recorded by electroencephalograph, stopped with anesthetic treatment. In MPA-treated rats extranigral damage was mild, with no differences apparent between anesthetics. Control animals sustained severe lesions in the substantia nigra pars reticulata (SNPR). No statistically significant differences between anesthetic groups were present, although an effect was suggested for midazolam to decrease SNPR lesional area (P = 0.06). In flurothyl-treated rats, there were significant reductions in SNPR neuropathologic grade (P = 0.025) and lesional area (P = 0.025) with midazolam. We conclude that midazolam attenuates postseizure SNPR damage in rats.
Kofke
W A
WA
Department of Anesthesiology, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey.
Towfighi
J
J
Garman
R H
RH
Graybeal
J M
JM
Housman
C
C
Hawkins
R A
RA
D015097:3-Mercaptopropionic Acid / Q000008:administration & dosage*; D000280:Administration, Inhalation; D000777:Anesthetics / Q000627:therapeutic use*; D000818:Animals; D001927:Brain Diseases / Q000209:etiology* / Q000517:prevention & control; D005481:Flurothyl / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D007530:Isoflurane / Q000627:therapeutic use; D007649:Ketamine / Q000627:therapeutic use; D008297:Male; D008874:Midazolam / Q000627:therapeutic use; D051381:Rats; D013226:Status Epilepticus / Q000139:chemically induced* / Q000150:complications; D013874:Thiopental / Q000627:therapeutic use
D000777:Anesthetics; D007649:Ketamine; D005481:Flurothyl; D015097:3-Mercaptopropionic Acid; D007530:Isoflurane; D013874:Thiopental; D008874:Midazolam